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Abstract
Mer is a receptor tyrosine kinase implicated in acute lymphoblastic leukemia (ALL), the most 
common malignancy in children. The currently available data provide a rationale for development 
of Mer kinase inhibitors as cancer therapeutics that can target both cell autologous and immune-
modulatory anti-tumor effects. We have previously reported several series of potent Mer inhibitors 
and the objective of the current report is to identify a chemically dissimilar back-up series that 
might circumvent potential, but currently unknown, flaws inherent to the lead series. To this end, 
we virtually screened a database of ∼3.8 million commercially available compounds using high-
throughput docking followed by a filter involving Structural Protein-Ligand Interaction 
Fingerprints (SPLIF). SPLIF permits a quantitative assessment of whether a docking pose interacts 
with the protein target similarly to an endogenous or known synthetic ligand, and therefore helps 
to improve both sensitivity and specificity with respect to the docking score alone. Of the total of 
62 experimentally tested compounds, 15 demonstrated reliable dose-dependent responses in the 
Mer in vitro kinase activity assay with inhibitory potencies ranging from 0.46 μM to 9.9 μM.
Introduction
Acute lymphoblastic leukemia (ALL) is the most frequent type of cancer in children and 
accounts for nearly 30% of all pediatric cancers[1]. Particularly, the T-cell ALL subtype has 
a poorer prognosis, with a 5-year relapse-free survival rate of 60–75% even with effective 
treatment[2]. Extensive conventional chemotherapeutic treatment often results in toxic side 
effects, such as organ damage, secondary malignancy or emergent chemoresistance[3]. Mer 
receptor tyrosine kinase, ectopically expressed in at least 50% of pediatric T-cell ALL 
samples, has been shown to play a role in ALL genesis[1, 3]. Moreover, Mer is not 
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expressed in normal T- and B-lymphocytes. Overall, the currently available data support a 
hypothesis that Mer kinase inhibitors might be developed into selective therapeutics for 
ALL. We have previously reported several series of potent Mer inhibitors, including 
compound 2 (see Figure 1) [4], resulting from structure-based design[4-9]. While our Mer 
project is progressing through IND enabling studies with an initial clinical candidate from 
this series, we are also working on identifying a chemically dissimilar back-up series that 
might circumvent potential flaws inherent to the current lead series. In such an endeavor, 
often referred to as lead- or scaffold-hopping, virtual screening, either structure- or 
pharmacophore-based, is often a tool of choice.
In Structure-based Virtual Screening (SB-VS), each small-molecule ligand is docked into 
the putative binding pocket of the protein in a number of energetically acceptable binding 
modes called poses [10], for each of which binding affinity is assessed using a scoring 
function [11]. While it is now generally accepted that most of the popular docking 
algorithms perform fairly well in generating sound poses, the scoring functions most often 
fail to adequately evaluate the binding affinity[12-18]. Hence, even the optimistic success 
rates that are generally reported in SB-VS benchmark studies[17, 18] might often be 
insufficient when screening large chemical libraries against a novel target with an objective 
to experimentally test 50 to 100 virtual hits. Therefore, all possible means must be deployed 
to improve the odds of getting a sizable number of confirmed actives out of very small sets 
of virtual hits. Of special interest are scoring approaches that can take advantage of known 
ligand-bound protein structures (e.g., enzyme-bound substrates) as these are likely to capture 
molecular interactions that are most important for high affinity binding. Here we made use 
of an approach termed Structural Protein-Ligand Interaction Fingerprints (SPLIF) that 
exploits this general idea of quantifying and comparing ligand-protein interactions[19]. In 
particular, in SPLIF, 3D-structures of interacting ligand and protein fragments are explicitly 
encoded in the fingerprint. Consequently, all possible interaction types that may occur 
between the fragments (e.g., π–π, CH–π, etc) are implicitly encoded into SPLIF. The 
reported fingerprints are used for calculation a normalized quantitative score that expresses 
the similarity between the interaction profile of a docking pose and that of a reference 
protein-ligand complex.
The study involved screening a collection of 3.8 million commercially available compounds 
using a popular docking tool Glide[20] followed by a SPLIF-rescoring step and a cluster-
based triage. Eventually, the 62 selected virtual hits were purchased and their inhibitory 
potency was assessed in the Mer Microfluidic Capillary Electrophoresis assay.
Materials and Methods
Small-molecule Dataset
The virtual collection of commercially available compounds was created from 5 large 
catalogs: Asinex, ChemDiv, Enamine, IBS and Life Chemicals. These vendors have been 
selected because they have their own, up-to-date stocks, offer affordable prices and high 
availability rates and are able to satisfy our shipping requirements. The resulting collection 
features ∼3.8 million compounds and is updated on a semi-annual basis via SD files 
provided by the vendors. The files used in this study have been uploaded between July and 
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December of 2011. Virtually all compounds satisfied our usual pre-VS filters, i.e., a 
softened version of the Lipinski rules[21] (2+ violations of Number of H-bond donors < 6, 
Number of H-bond acceptors < 12, Molecular Weight between 200 and 600, ALogP < 5.5) 
and REOS[22]. Chemical structures of all screened compounds were cleaned using 
PipelinePilot software[23]. The cleaning protocol included salt stripping, mixture splitting, 
functional group standardization and charge neutralization. Ionizable compounds were 
converted to their most probable charged species at pH 7.4. Pipeline Pilot was then used for 
3D conversion.
Docking
Small-molecule structures were docked into the active site of the target proteins using the 
Glide program [20] in standard docking precision (Glide SP). The binding region was 
defined by a 20Å × 20Å × 20Å box centered on a reference ligand. A scaling factor of 0.8 
was applied to the van der Waals radii. Default settings were used for all the remaining 
parameters. The top 3 poses were generated for each ligand and subjected to SPLIF scoring.
Structural Protein-Ligand Interaction Fingerprints (SPLIF)
SPLIF scoring consists of two steps: 1) generating SPLIF for the current docking pose and 
2) calculating similarity between the current and reference SPLIFs. The details of the 
technique have been described in our earlier work[19]. In this study, Functional 
Connectivity Fingerprints up to the second closest neighbor (FCFP4) from the Pipeline Pilot 
software[23] were used as SPLIF bits. The SPLIF-based similarity score was calculated as 
follows:
(1)
where NUMLA is the number of Unique Matching Ligand Atoms, i.e., atoms constituting the 
matching circular fragments of the docking pose compared to the reference (on the ligand 
side); NULA is the number of Unique Ligand Atoms, i.e., atoms constituting all interaction 
fingerprints of the docking pose (on the ligand side); NUMPA is the number of Unique 
Matching Protein Atoms, i.e., atoms constituting the matching circular fragments of the 
docking pose compared to the reference (on the protein side); NUPA is the number of Unique 
Protein Atoms, i.e., atoms constituting all interaction fingerprints of the docking pose (on 
the protein side). The whole workflow was implemented in Pipeline Pilot[23]. The 
constituent algorithms were developed in Pipeline Pilot Script. The current implementation 
allows processing of ∼10 poses per second in screening mode.
Reference structures
Three high-resolution crystal structures of the Mer protein kinase domain were used in this 
study: i) in complex with adenosine diphosphate (ADP) (resolution 1.90 Å; PDB code: 
3BRB)[24]; (ii) in complex with a weakly potent inhibitor C-52 (1) (resolution 2.80 Å; PDB 
code: 3BPR)[24]; and in complex with a highly potent inhibitor UNC569 (2), previously 
reported by us (resolution 2.69 Å; PDB code: 3TCP)[4]. Because we did not intend to mimic 
Da et al. Page 3






















the phosphate groups of ATP, as ligands including these interactions are highly unlikely to 
be cell penetrant, we stripped them to yield the reference ligand 3. The reference ligand 
structures are shown in Figure 1.
The corresponding PDB files were processed as follows. Hydrogen atoms were added to the 
protein, the active site was visually inspected and appropriate corrections were made for 
tautomeric states of histidine residues, orientations of hydroxyl groups, and protonation 
states of basic and acidic residues. The hydrogen atoms were energy minimized in the 
MMFF force field[25] using the Macromodel software with the Maestro graphics 
interface[26] with all the non-hydrogen atoms constrained to their original positions.
Hit analysis and selection
After virtual hits were selected based on a combination of Glide and SPLIF scores, they 
were subjected to a hit triage process. The triage was based upon a number of objective and 
subjective criteria. The objective criteria included (i) redundancy reduction, by dropping 
some ligands belonging to large clusters, i.e., groups of chemically similar compounds; and 
(ii) elimination of compounds that are highly dissimilar from other virtual hits (also called 
singletons). Both redundancy reduction and singleton elimination were performed by means 
of the Pipeline Pilot software[23]. Redundancy reduction consisted of two steps. First, the 
virtual hits were grouped into clusters with members similar at ≥45% (Tanimoto; ECFP4 
fingerprints). The clustering method used at this step was Maximum Dissimilarity clustering 
without limitation on the maximum number of clusters and with the number of re-center 
steps set to zero[23]. In the next step, 20% to 50% of compounds were then selected from 
each cluster in such a way that larger clusters contributed smaller percentages. The output 
ligands were aligned to their respective Maximum Common Substructures to facilitate the 
subsequent visual ad hoc selection. To facilitate an ad hoc hit selection / elimination we 
have created a hit list, in which each cluster was represented by a single (central) compound.
Mer Microfluidic Capillary Electrophoresis assay
Inhibition of Mer kinase activity by analogues was tested using a microfluidic capillary 
electrophoresis (MCE) assay, in which phosphorylated and unphosphorylated substrate 
peptides were separated and analyzed through a LabChip EZ Reader[27, 28].
Compound testing was performed in a 384 well, polypropylene microplate in a final volume 
of 50 μL in 50 mM Hepes, Ph 7.4 containing 0.1% Bovine Serum Albumin (BSA), 0.1% 
Triton X-100, 10 mM MgCl2 and ATP at 5 μM. All reactions were terminated by addition of 
50 μL of 70 mM EDTA. Phosphorylated and unphosphorylated substrate peptides were 
separated following a 180 minute incubation on a LabChip EZ Reader equipped with a 12-
sipper chip in separation buffer supplemented with CR-8 and analyzed using EZ Reader 
software. The reaction was run at 2 nM enzyme concentration. More details can be found in 
our previous work[4, 6].
Quality control of compound samples
Quality control of the purchased and screened compounds was performed by diluting 1 μL 
of DMSO stock solution (10mM concentration) with 49 μL of MeOH. The sealed plate was 
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then directly used to inject 5 μL from each well onto an Agilent 6110 Series LC/MS system 
with the UV detector set to 220 nm. Samples were injected onto an Agilent Eclipse Plus 4.6 
× 50 mm, 1.8 μM, C18 column at room temperature. A mobile phase of A being H2O + 
0.1% acetic acid and B being MeOH + 0.1% acetic acid was used. A linear gradient from 
10% to 100% B in 5.0 min was followed by pumping 100% B for another 2 minutes with a 
flow rate of 1.0 mL/min. Mass spectra (MS) data were acquired in positive ion mode using 
an Agilent 6110 single quadrupole mass spectrometer with an electrospray ionization (ESI) 
source. The purity of all compounds was found to be 95% or higher by UV absorption at 
220 nm, 254 nm and 280 nm and the MS+1 peak was consistent for the purchased structure.
Results and Discussion
Mer[1] is protein kinase belonging to the receptor tyrosine kinase subfamily that might be 
considered – after a long record of success stories[29] – as a “low-hanging-fruit” target. 
However, in our biochemical assay, Mer was sensitive to only a few known kinase 
inhibitors. Moreover, the nanomolar potency Mer inhibitor UNC569 (compound 2) has 
shown significant selectivity when screened against a broad protein kinase panel[4] and the 
outcome of our random diversity screen suggests a very low rate of potent Mer inhibitors in 
diverse sets of commercially available compounds (see detail below). All the above suggests 
that a post-docking filtration of docking poses based on prior knowledge of ligand-protein 
interactions would be of particular interest in order to reduce the false positive and false 
negative rates that characterizes unfiltered structure-based screening[17, 30].
In this study, the generic VS workflow included the following steps: (i) Glide-based docking 
and scoring; (ii) SPLIF-based scoring; (iii) hit selection based on the analysis of the Glide 
and SPLIF scores; and (iv) hit triage. The latter step involved three components: (i) 
diversity-based selection as described in Materials and Methods; (ii) a subjective triage, such 
as dropping clusters that the chemists would not like to follow-up on even if they contain 
some true actives; and (iii) unexpected reasons that result in elimination of some virtual hits 
from the list, such as compound price or stock depletion. The initial pre-filtering of docking 
poses by means of a conventional scoring function (G-score in this study) has been validated 
in our earlier benchmark study [31].
SPLIF Reference System
When characterizing the lead series in our previous study[4], we obtained an X-ray structure 
of the Mer kinase domain in complex with compound 2. In addition to the latter ligand-
protein complex with a highly potent inhibitor, there are two more ligand-bound Mer 
structures: with a weak inhibitor (ca. 10 μM), C-52 (1), and the co-factor ATP (3). We 
merged all three reference ligands into a single superligand, so that any docking pose 
matching one fragment in one reference fingerprint and another fragment in a different 
reference fingerprint would get a higher SPLIF-score than if it is compared to one reference 
ligand at a time. Overall, 1,330 SPLIF bits have been generated for this reference Mer-
bound superligand. The above SPLIF-bits result from 138 FCFP-bits on the protein side 
(constituted by 53 unique atoms) and 139 FCFP-bits on the ligand side (36 unique atoms).
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Screening workflow and statistics
Glide docking of 3.8 million commercial compounds yielded 1.56 million compounds with 
poses showing G-scores better than 0 kcal/mol (see Figure 2a for the G-score probability 
density distribution). The G-score distribution is quasi-normal with a mean at ∼-5 kcal/mol 
and a standard deviation of ∼1 kcal/mol. To start the selection process, we had to set a G-
score threshold that would eliminate the least likely true Mer inhibitors. To this end, we 
made use of probability density distributions of known Mer actives and inactives. By this 
time, our chemical optimization program had generated 385 Mer actives (IC50 < 1 μM) and 
409 inactives (IC50 > 30 μM). Both actives and inactives were docked using the same 
protocol as described in Materials and Methods. Their G-score distributions (see Figure 2b) 
indicate that a G-score threshold of -6 kcal/mol adequately separates actives from inactives 
with optimal false positives vs false negatives rates. Therefore, assuming similar 
distributions for the 1.5 million scored compounds, the G-score threshold for the virtual 
screening campaign was set to -6 kcal/mol, which resulted in a selection of 403,581 
compounds.
All poses resulting from the G-score selection were submitted to SPLIF-score calculation 
with the ultimate goal of obtaining a manageable list of hit-candidates that can be subjected 
to hit triage and, ultimately, experimental testing. Again, we made use of known Mer actives 
and inactives (as described in the previous paragraph) to determine an optimal SPLIF-score 
threshold. As can be seen in Figure 2d, an optimal actives/inactives separation occurs at a 
threshold of ∼0.35. Consistently, the value of 0.35 is where the SPLIF-score distribution for 
403,581 preselected compounds approaches zero (see Figure 2c) and hence hits having 
higher SPLIF-scores may be considered as outliers to the baseline distribution (i.e., 
distribution of inactives). The retained SPLIF-score threshold of 0.35 resulted in a selection 
of 10,862 SPLIF-based hit-candidates. These candidates were subjected to a diversity-based 
selection as described in Materials and Methods. In addition, 544 cluster centers have been 
visually inspected and a few clusters have been dropped as inappropriate lead-candidates 
(e.g., nucleotides, steroids, etc.). A few more selected virtual hits were out of stock. 
Eventually, 62 compounds have been purchased and tested in the Mer microfluidic capillary 
electrophoresis assay.
It is noteworthy that the SPLIF score alone was not enough to efficiently rank docking 
poses. Indeed, more than 40,000 compounds satisfy the SPLIF-score threshold of 0.35. This 
result is consistent with an intuitive anticipation that even if a fraction of a ligand mimics an 
existing x-ray pose, the rest of it may strongly diminish its binding affinity. Therefore, 
SPLIF-scoring should only be applied to likely binders, where “likely” means that they need 
to have a satisfactory preliminary docking score.
Hit analysis
Of the total of 62 experimentally tested compounds, 15 demonstrated reliable dose-
dependent responses in the Mer microfluidic capillary electrophoresis assay with inhibitory 
potencies ranging from 0.46 μM to 9.9 µM (see Figure 3 and Table 1). Remarkably, 2 hits, 4 
and 5, demonstrated mid-nanomolar potencies of respectively 0.46 μM and 0.60 μM. 
Despite relatively low potencies of the other hits, they still may be worth consideration as 
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potential leads due to fairly high ligand efficiencies (LE)[32]. The LE values were 
calculated as pIC50 normalized by the number of heavy atoms and are given in Table 1. The 
LE values for the 15 confirmed actives range between 0.17 and 0.34 and are comparable to 
LE of the current lead (compound 2; LE=0.11).
These 15 hits represent distinguishable scaffolds, such as thieno[3,2-c]quinolones (4 and 5), 
pyrimidin-2-amines (6, 7, 8, 10, 11, 15 and 17), pyrimidine-fused heterocycles (9, 13, 16 
and 18), as well as singletons 12 and 14. Their inhibitory potencies are weaker than the 
potency of the reference ligand 2, but most of them demonstrate lead-like[33] profiles and 
may serve as valuable starting points for further chemical optimization. In our previous 
study we showed that on a broad panel of targets SPLIF-scores were not redundant with 
respect to other ranking schemas that could have been used in a similar setting (e.g., G-score 
alone, 2D- or SIFt-similarity to known actives [34]). As can be seen in Table 1, in the 
current study, G-score ranks for the 15 confirmed actives range from 39,335 to 349,812 
(#96,049 for the most potent compound 4), which means that none of them would have been 
shortlisted for purchase using that method alone.
All confirmed hits provide strong evidence that using SPLIF-score as a post-docking filter 
does not undermine the scaffold-hopping capacity of SBVS. Indeed, none of the 15 actives 
feature a chemical scaffold identical to any reference compound (1-3). However, despite the 
clear structural differences between, for example, the most potent hit 4 and the reference 
compound 2, their respective docking poses look intuitively similar (see Figure 4) and make 
the same key interactions.
Finally, we also assessed the overall efficiency of our virtual screening run by comparing its 
hit rate (i.e., 15 hits / 62 tested = 24%) and to that of a random diversity screen. To this end, 
we have screened 10 randomly selected 384-well (320-ligand) plates in a single-dose run (at 
10 μM; in duplicate) in the Mer microfluidic capillary electrophoresis assay. Only six 
compounds of the 3,200 screened have shown activity beyond a threshold of 30% (that is a 
consensus of both statistical and potency significance) resulting in 0.12% hit rate (4 hits / 
3,200 tested). Therefore, our SPLIF-based SBVS has demonstrated a ∼200-fold (24% / 
0.12%) improvement over a random screen.
Conclusions
In this paper, we report new template starting points for inhibitors of Mer, a receptor 
tyrosine kinase and a potential therapeutic target for the treatment of ALL and other 
cancers[35]. We performed SBVS against a database of ∼3.8 million commercially 
available compounds. In order to improve the odds of success, a recently introduced SPLIF-
score [31] was used as a post-docking filter that quantitatively assesses whether a docking 
pose interacts with the protein target similarly to reference ligand. A total of 62 SPLIF-based 
virtual hits have been purchased and tested in the Mer MCE assay. Fifteen tested compounds 
demonstrated reliable dose-dependent inhibitory potencies with IC50's ranging from 0.46 μM 
to 9.9 μM. The hits identified have high ligand efficiencies, show lead-like property profiles 
and represent new chemical motifs that might be used as starting points for further chemical 
optimization. Additionally, this study confirms our previous findings [31] that SPLIF can 
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significantly improve the success rate of SBVS while conserving its inherent scaffold-
hopping ability.
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Reference ligand structures for SPLIF scoring.
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Figure 2. a) The distribution of Gscores of 1.5 million acceptable compounds for virtual 
screening after docking to the Mer active site; b) the distributions of Gscores of in-house 
identified Mer actives and inactives; c) the distribution of SPLIF-scores of remaining 400K 
compounds after the Gscore filter being applied; d) the distribution of SPLIF-scores of in-house 
identified Mer actives and inactives.
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Figure 3. Chemical structures of 15 confirmed Mer actives
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Figure 4. A docking pose of the most potent hit 4 (green) overlaid with the reference ligand 2 
(magenta)
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